Shusil Pandit

Dr. Shusil Pandit

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Developmental Cell
Verified
Journal Article
Closed access
JLJing Li
Jing Li
CRCong Ran
Cong Ran
ELEdward Li
Edward Li
FGFaye Gordon
Faye Gordon
GCGrant Comstock
Grant Comstock
ABAlain de Bruin
Alain de Bruin

1 November 2013 in Trends in Cell Biology
Verified
Journal Article
Closed access
SPShusil Pandit
Shusil Pandit
BWBart Westendorp
Bart Westendorp
ABAlain de Bruin
Alain de Bruin

14 October 2012 in Nature Cell Biology
Verified
Journal Article
Closed access
SPShusil Pandit
Shusil Pandit
BWBart Westendorp
Bart Westendorp
SNSathidpak Nantasanti
Sathidpak Nantasanti
ELElsbeth van Liere
Elsbeth van Liere
PTPeter C. J. Tooten
Peter C. J. Tooten
ABAlain de Bruin
Alain de Bruin

5 June 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DGDavide Genini
Davide Genini
LBLara Brambilla
Lara Brambilla
ELErik Laurini
Erik Laurini
JMJessica Merulla
Jessica Merulla
GCGianluca Civenni
Gianluca Civenni
CCCarlo Catapano
Carlo Catapano
Significance: The transcription factor STAT3 is involved in multiple oncogenic signaling pathways and is an attractive therapeutic target. This study shows that a potent inhibitor of STAT3 interferes with mitochondrial activity and protein homeostasis, leading to a synthetic lethality effect in glucose-depleted cancer cells. These findings provide a rationale for novel strategies based on the use of STAT3 inhibitors for cancer treatment.

25 July 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LKLindsey N. Kent
Lindsey N. Kent
JRJessica B. Rakijas
Jessica B. Rakijas
SPShusil Pandit
Shusil Pandit
Bart WestendorpBart Westendorp
Bart Westendorp
HCHui-Zi Chen
Hui-Zi Chen
GLGustavo Leone
Gustavo Leone
E2F-mediated transcriptional repression of cell cycle–dependent gene expression is critical for the control of cellular proliferation, survival, and development. E2F signaling also interacts with transcriptional programs that are downstream of genetic predictors for cancer development, including hepatocellular carcinoma (HCC). Here, we evaluated the function of the atypical repressor genes E2f7 and E2f8 in adult liver physiology. Using several loss-of-function alleles in mice, we determined that combined deletion of E2f7 and E2f8 in hepatocytes leads to HCC. Temporal-specific ablation strategies revealed that E2f8’s tumor suppressor role is critical during the first 2 weeks of life, which correspond to a highly proliferative stage of postnatal liver development. Disruption of E2F8’s DNA binding activity phenocopied the effects of an E2f8 null allele and led to HCC. Finally, a profile of chromatin occupancy and gene expression in young and tumor-bearing mice identified a set of shared targets for E2F7 and E2F8 whose increased expression during early postnatal liver development is associated with HCC progression in mice. Increased expression of E2F8-specific target genes was also observed in human liver biopsies from HCC patients compared to healthy patients. In summary, these studies suggest that E2F8-mediated transcriptional repression is a critical tumor suppressor mechanism during postnatal liver development.

30 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SPShusil Pandit
Shusil Pandit
GSGiada Sandrini
Giada Sandrini
JMJessica Merulla
Jessica Merulla
VNValentina Nobili
Valentina Nobili
XWXin Wang
Xin Wang
CCCarlo Catapano
Carlo Catapano
The multi-kinase inhibitor sorafenib is a primary treatment modality for advanced-stage hepatocellular carcinoma (HCC). However, the therapeutic benefits are short-lived due to innate and acquired resistance. Here, we examined how HCC cells respond to sorafenib and adapt to continuous and prolonged exposure to the drug. Sorafenib-adapted HCC cells show a profound reprogramming of mitochondria function and marked activation of genes required for mitochondrial protein translation and biogenesis. Mitochondrial ribosomal proteins and components of translation and import machinery are increased in sorafenib-resistant cells and sorafenib-refractory HCC patients show similar alterations. Sorafenib-adapted cells also exhibited increased serine 727 phosphorylated (pSer727) STAT3, the prevalent form in mitochondria, suggesting that STAT3 might be an actionable target to counteract resistance. Consistently, a small-molecule STAT3 inhibitor reduces pSer727, reverts mitochondrial alterations, and enhances the response to sorafenib in resistant cells. These results sustain the importance of mitochondria plasticity in response to sorafenib and identify a clinically actionable strategy for improving the treatment efficacy in HCC patients.